Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | PSMB9 | P28065 | 9/20 | 0.31 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7914476 | 1.00 | CTSB (0.41) | CTSBCTSSPSMB9PSMB8 | |
| SCHEMBL15509453 | 1.00 | CTSB (0.41) | CTSBCTSSPSMB9PSMB8 | |
| SCHEMBL15509452 | 1.00 | CTSB (0.41) | CTSBCTSSPSMB9PSMB8 | |
| SCHEMBL15509451 | 1.00 | CTSB (0.41) | CTSBCTSSPSMB9PSMB8 | |
| SCHEMBL13502758 | 0.89 | CTSB (0.40) | CTSBCTSS | |
| SCHEMBL8246800 | 0.88 | CTSB (0.34) | CTSBCTSSPSMB9PSMB8 | |
| SCHEMBL11976284 | 0.88 | CTSB (0.42) | CTSBCTSS | |
| SCHEMBL11976283 | 0.88 | CTSB (0.41) | CTSBCTSS | |
| SCHEMBL13082504 | 0.88 | CTSB (0.42) | CTSBCTSS | |
| Hydrochloric Acid SCHEMBL4522873 | 0.87 | CTSB (0.41) | CTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477980-B1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2016-06-08 | — | — | EP | disclosed |
| US-8765667-B2 | HCV protease inhibitors | EISSENSTAT MICHAEL (US) | 2014-07-01 | — | — | US | disclosed |
| US-20110182854-A1 | HCV PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2010107739-A2 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2007015824-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182854-A1 | HCV PROTEASE INHIBITORS | SERPINB1, CTSC, HPN | CTSB 31/4885CTSS 33/4885PSMB9 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.